STAAR Surgical (STAA) Q1 2026 Earnings Transcript

STAAR Surgical reported Q1 net sales of $93.5 million, up 119.6% year over year, with adjusted EBITDA swinging to a $24.4 million profit from a $26.3 million loss and net income reaching $5.2 million. China sales reached $47.4 million on EVO+ launch strength, U.S. sales topped $6 million and rose 22%, and gross margin expanded to 73.6% as operating expenses fell 18% on a comparable basis. Management reiterated a $225 million 2026 spending target but stayed cautious on guidance due to macro, geopolitical, pricing, and inventory risks.

Analysis

The key setup is not just a profit rebound; it is a reset of the earnings power denominator. With China inventory normalized and channel sell-through now closer to true end-market demand, the next few quarters should be much less noisy, which materially improves the quality of the revenue signal and should compress the market’s discount for “is this real?” around the China print. That matters because the business is transitioning from a balance-sheet/inventory clean-up story into a volume-and-mix story, where every incremental unit should carry much higher marginal contribution than the market has historically assumed.

The second-order winner is the Swiss manufacturing footprint. If Nidau can genuinely supply the China portfolio tariff-free at scale, the company is no longer just mitigating cost; it is structurally defending gross margin against geopolitical friction while creating a local-for-global cost advantage that competitors without similar flexibility will struggle to match. The flip side is that the current margin bounce may be partly front-loaded: if EVO+ adoption remains premium, there is upside, but if price competition intensifies or product mix shifts back toward lower-ASP configurations, the margin path could flatten before the street rebuilds confidence.

The biggest risk is that investors extrapolate Q1 into a clean quarterly cadence too early. Management is implicitly telling you that Q2/Q3 seasonality is still unproven under the new operating regime, and the macro/geopolitical hedge is not boilerplate—this business still has meaningful single-country and region-specific exposure, so a disruption in China, the Middle East, or India can quickly mask underlying demand strength. The market should view this as a quality-improvement story with a real catalyst, but not yet a fully de-risked growth annuity.

Contrarian read: consensus is likely underestimating how much the U.S. label expansion and the broader shift away from corneal-ablation procedures can matter over 12-24 months, even if near-term revenue remains China-led. The strategic question is whether STAAR can use this window to convert a cyclical inventory recovery into a durable refractive platform franchise; if execution holds, the rerating can continue, but if guidance remains withheld into multiple clean quarters, the stock may plateau as the market waits for proof beyond one strong print.

Key Decisions for Investors

• Long STAA into the next 4-8 weeks on any pullback if the market over-focuses on lack of guidance; risk/reward favors owning the stock while China sell-through and tariff-free Swiss supply are still underappreciated. Use a tighter stop if Q2 commentary shows inventory drifting above target.
• Pair trade: long STAA / short ALC for 1-2 quarters. STAAR has the cleaner operating leverage from a normalized inventory base, while ALC is more exposed to a slower premium-consumer spending cycle and a less obvious near-term catalyst path.
• Buy STAA call spreads 3-6 months out to express upside from a clean Q2/Q3 seasonal reacceleration without paying full upside premium. Favor structures that monetize a rerating toward a more credible 2026 operating margin story.
• Avoid chasing the stock after the first post-earnings move higher; wait for evidence that Q2 converts into higher sell-through rather than channel restocking. The trade works best if the market remains skeptical for another reporting cycle.
• Monitor ORCL only as an indirect supplier beneficiary; no direct trade needed, but the ERP rollout is a medium-term execution risk reducer. If Oracle implementation becomes disruptive, reduce STAA exposure quickly because the multiple is now more sensitive to operational slippage.